Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14135 | 1.00 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL8121 | 1.00 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL2343819 | 0.89 | ELANE (0.35) | ELANENOS1 | |
| SCHEMBL17560519 | 0.89 | ELANE (0.35) | ELANENOS1 | |
| SCHEMBL17654422 | 0.89 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL2127300 | 0.89 | ELANE (0.35) | ELANENOS1 | |
| SCHEMBL13518677 | 0.89 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL13518680 | 0.89 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL25504021 | 0.89 | ELANE (0.32) | ELANENOS1 | |
| SCHEMBL24177802 | 0.89 | PCSK9 (0.33) | ELANEPCSK9NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516049-B2 | Sulfonylurea ring substituted monocyclic β-lactam antibiotics | SUZHOU ERYE PHARMACEUTICAL CO., LTD (CN) | 2026-01-06 | — | — | US | disclosed |
| EP-3528813-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEV 1 INC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4469441-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | Parion Sciences, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2024-11-28 | — | — | US | disclosed |
| US-12077543-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| WO-2024123663-A1 | ANTIMICROBIAL COMPOUNDS | SRI INTERNATIONAL (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024092256-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-02 | — | — | WO | disclosed |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| WO-2003051797-A2 | SMALL-MOLECULE INHIBITORS OF INTERLEUKIN-2 | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030087950-A1 | New alpha-amino acid sulphonyl compounds | LES LABORATOIRES SERVIER (FR) | 2003-05-08 | — | — | US | disclosed |
| EP-1245568-A1 | Sulfonyl derivatives of amino acids and their use as inhibitors of dipeptidyl-peptidase IV (DPP IV) | Les Laboratoires Servier (FR) | 2002-10-02 | — | — | EP | disclosed |
| EP-1187825-A1 | THIOPHENE INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2002-03-20 | — | — | EP | disclosed |
| US-6274620-B1 | 2-BENZENESULFONYLAMINO-3-((5-BROMO-THIOPHENE-2-CARBONYL)-AMINO )PROPIONIC ACID-TERT-BUTYL ESTERS AS ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; OSTEOPOROSIS, RESTENOSIS, AND OCULAR NEOVASCULARIZATION | BIOCHEM PHARMA INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| EP-1115724-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000078723-A1 | PROCESS FOR THE PREPARATION OF BUTOXYCARBONYLIMINO COMPOUNDS AND INTERMEDIATES THEREFOR | GLAXO GROUP LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000078723-A1 | PROCESS FOR THE PREPARATION OF BUTOXYCARBONYLIMINO COMPOUNDS AND INTERMEDIATES THEREFOR | GLAXO GROUP LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000075129-A1 | THIOPHENE INTEGRIN INHIBITORS | SHIRE BIOCHEM INC. (CA) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000017197-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | BIOCHEM PHARMA INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | RAB9A 769/4885ELANE 221/4885PCSK9 516/4885 |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | RAB9A 3740/4885ELANE 3995/4885PCSK9 3340/4885 |
| US-20030087950-A1 | New alpha-amino acid sulphonyl compounds | DNPEP, DPP4, DPP7 | RAB9A 1612/4885ELANE 985/4885PCSK9 3377/4885 |
| US-12077543-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | RAB9A 2320/4885ELANE 2136/4885PCSK9 4727/4885 |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | RAB9A 2320/4885ELANE 2136/4885PCSK9 4727/4885 |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | RAB9A 638/4885ELANE 1006/4885PCSK9 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.